These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34267345)

  • 1. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers.
    Liu L; Li W; Yang L; Guo ZT; Xue H; Xie NJ; Chen XY
    Acta Pharmacol Sin; 2022 Apr; 43(4):1082-1090. PubMed ID: 34267345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of almonertinib and its active metabolite HAS-719 in human plasma by LC-MS/MS: Evaluation of pharmacokinetic interactions.
    Liu L; Yang L; Li W; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1197():123231. PubMed ID: 35344780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
    Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
    J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
    Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
    Zhu YT; Zhang YF; Jiang JF; Yang Y; Guo LX; Bao JJ; Zhong DF
    Invest New Drugs; 2021 Aug; 39(4):1011-1018. PubMed ID: 33506323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.
    Chen J; Li J; Wu J; Song Y; Li L; Zhang J; Dong R
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1252. PubMed ID: 39073244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
    Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
    Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
    Hoch M; Huth F; Sato M; Sengupta T; Quinlan M; Dodd S; Kapoor S; Hourcade-Potelleret F
    Clin Transl Sci; 2022 Jul; 15(7):1698-1712. PubMed ID: 35616006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
    Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.
    Hu X; Hsieh CY; Zhang Y; Liu W; Xu S; Cai SX; Liu L; Zhang M; Shi H; Zhang H; Liu P; Li X; Xu P
    Br J Clin Pharmacol; 2023 Jun; 89(6):1767-1779. PubMed ID: 36458825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
    Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
    Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
    Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study.
    Huang Y; Jia Y; Chen X; Wang C; Wang Y; Wang M; Wu P; Shen J
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):1005-1013. PubMed ID: 38053514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.